Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Selects Hemophilia Candidate, Releases Preclinical Data


Alnylam Pharmaceuticals this week announced new preclinical data showing that its investigational RNAi-based treatment for hemophilia, ALN-AT3, could achieve target gene knockdown after subcutaneous administration to both mice and non-human primates.

ALN-AT3 comprises siRNAs targeting antithrombin, an endogenous inhibitor of thrombin generation, delivered using Alnylam's proprietary GalNAc-siRNA conjugate delivery technology. Alnylam said that it had been considering going after another natural anticoagulant protein, protein C, but that antithrombin proved to be the superior target.

According to the new data, which were presented at the World Federation of Hemophilia World Congress in Paris, “ALN-AT3 demonstrated potent activity in both mice and non-human primates, with an ED50 for AT plasma protein knockdown of approximately 1 mg/kg after a single subcutaneous dose,” Alnylam said.

“Studies showed a very durable response, where a single subcutaneous dose of ALN-AT3 achieved nadir knockdown of AT at about day 10, with effects lasting over 25 days,” the company added. “These data support a once-a-week or twice-a-month subcutaneous dosing paradigm.”

“We believe our new results demonstrate key proof of concept with this strategy as administration of ALN-AT3 was shown to improve thrombin generation in animal models of hemophilia,” Alnylam CMO Akshay Vaishnaw said in a statement.

The company said it expects to file an investigational new drug application for ALN-AT3 in 2013.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.